Singapore, July 15, 2022 (GLOBE NEWSWIRE) — Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights:
- Global and Regional Market Size Insight 2022 Till 2028
- Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till 2028
- Cancer Vaccine Market Insight & Forecast By 10 Different Cancers 2022 Till 2028
- Approved Cancer Vaccines Patent, Price, & Dosage Analysis
- Insight On More Than 350 Cancer Vaccines in Clinical Trials
- Cancer Vaccines Trials Insight By Company, Country and Indication
- Insight On More Than 20 Cancer Vaccines Commercially Available In Market
Download Report: https://www.kuickresearch.com/report-global-cancer-vaccine-market-size
Research on cancer immunotherapy has made tremendous progress with the introduction of several approaches including vaccines. Currently a cocktail of cancer vaccines have gained entry into the market including Gradasil 9, Cervarix, Provenge, Cecolin, and several others. The approval of these vaccines has shown robust response in the prevention of HPV associated cancers as well as in the management of prostate cancer, lung cancer, and pancreatic cancer. The huge clinical success of cancer vaccines has propelled the research and development activities in this domain. For instance in 2022, Immunity Bio has submitted biologic license application to US FDA to N-803 plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or…
